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Introduction: Ependymomas are rare glial tumors of the brain representing less than 5% of brain tumors. However,
spinal cord ependymomas in adults account for over 60% of all ependymomas including those arising from the
filum terminale and only 40% are intracranial. Reports of the appearance of another neoplasia at a different location
in patients with spinal ependymoma are scarce.
Methods: We searched PubMed for studies related to spinal cord ependymomas published over the last 30 years
(from January 1984) and retrieved 1197.
Results: We identified only two studies that met our criteria and we found an incidence of 9% of secondary neoplasias
after treatment for spinal ependymoma. The neoplasms were diagnosed from 2 months to 20 years after patients
underwent surgery for intraspinal ependymoma. These included pancreatic cancer, prostate cancer, Hodgkin lymphoma,
intracranial meningioma, mucin-producing pulmonary adenocarcinoma, gastric cancer and astrocytoma.
Conclusions: The genetic abnormalities affecting patients with spinal ependymomas may indicate a predisposition to
the development of secondary cancers or a general failure of the repairing mechanism in their DNA. The unaffected
survival rates in those individuals permit for a long period the accumulation of different mutations on the genome and
thus the appearance of a second cancer. However, more studies are needed, particularly in young patients with high
survival rates.
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Ependymomas are rare glial tumors of the brain repre-
senting less than 5% of brain tumors [1-3]. However,
spinal cord ependymomas in adults account for over
60% of all ependymomas including those arising from the
filum terminale and only 40% are intracranial. According
to the World Health Organization (WHO) classification,
ependymomas are divided into three subtypes: subependy-
momas and myxopapillary ependymomas (MEPNs; WHO
grade I), classic ependymomas (WHO grade II), and ana-
plastic ependymomas (WHO grade III). Compared with
intracranial ependymomas, spinal ependymomas have a
better prognosis [4] and gross total resection (GTR) is the
gold standard in surgical treatment [5-9]. Thus they must
be considered a unique clinical entity requiring specific
management. MEPNs represent 13% of all ependymomas* Correspondence: gfotakop@yahoo.gr
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unless otherwise stated.and are mainly found in the cauda equina, with occasional
extension into the conus medullaris [10]. The remaining
spinal cord ependymomas generally consist of the classic
ependymoma type, which are primarily located in the cer-
vical and thoracic regions [11].
Although cerebrospinal fluid metastasis occurs in 7%
of patients with spinal ependymomas [12], multiple pri-
mary tumors in the central nervous system of different
histological cell types are rare and more unusual seems
to be the incidence of the development of a second can-
cer. This observation has not been reported in other
tumor types and the mechanism still remains unclear.
The purpose of the present study was to investigate the
development of the second cancer in patients treated for
spinal cord ependymomas.Results
After investigation of 1197 articles, only two articles
were eligible [13,14]. There were 100 patients surgicallyentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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age age at diagnosis was 41.67±18 years (range, 7 to
79 years) with a male-to-female ratio of 1.12:0.88. The
study included two children. The most common pre-
senting symptoms were local back pain (69.5%), radicu-
lar pain (70.5%) and urinary incontinence (19%). Mean
time from symptom occurrence to diagnosis was 18.7
months (range, 1 month to 20 years). Mean follow-up
time was 71.5 months (range, 2 months to 21 years). At
primary surgery, the histological classification of tumors
was as follows: MEPN (WHO grade I), 46 patients (46%);
ependymoma (WHO grade II), 52 patients (52%); and ana-
plastic ependymoma (WHO grade III), two patients (2%).
The tumors were located in the thoracic segment (n=16),
cervical segment (n=18), conus medullaris (n=30), cauda
equina (n=6), and filum terminale (n=28; Table 1). All tu-
mors were operated through a posterior approach. GTR
was performed in 73 patients (73%), subtotal resection in
26 patients (26%) and one patient (1%) underwent biopsy.
Sixteen patients received radiotherapy after GTR (16/73
or 21.91%), one of these developed local recurrence and
in three cases tumors scattered or metastasized. Six
patients had a cerebrospinal fluid leak after surgery.
Within the follow-up period, tumor recurrence was 8.21%
(6/73 cases) in those patients who had undergone GTR.
No association was found between age, tumor location,
Ki-67 index, and recurrence of disease.
Secondary cancer in both studies was found in nine
patients out of 100 suggesting that 9% of patients mightTable 1 Baseline characterictics of patients
Patients’ characteristics Number %
Female 47 47
Location
1. Cervical 18 18
2. Thoracic 16 16
3. Conus medullaris 30 30
4. Filum terminale/cauda equine 36 36
Histology
1. Myxopapillary ependymoma (grade I) 49 49
2. Ependymoma (grade II) 48 48
3. Anaplastic ependymoma (grade III) 3 3
Secondary cancer
1. Gastric cancer 2 2
2. Lung cancer 2 2
3. Astrocytoma 1 1
4. Prostatic cancer 1 1
5. Pancreatic cancer 1 1
6. Hodgkin lymphoma 1 1
7. Intracranial meningioma 1 1develop a secondary cancer. The neoplasms were diag-
nosed 2 months to 20 years after patients underwent
surgery for intraspinal ependymoma. These included
pancreatic cancer, prostate cancer, Hodgkin lymphoma,
intracranial meningioma, mucin-producing pulmonary
adenocarcinoma, gastric cancer and astrocytoma (Table 1).
In addition, only one patient (who later developed intra-
cranial meningioma) had received radiotherapy, and the
neoplasm was outside the radiation field. The remaining
eight patients who developed a second cancer did not
receive radiation therapy.
Discussion
After performing a study on spinal ependymomas we
found an increased incidence of secondary cancer [14].
Based on that, we set out to investigate whether other
studies assessed the occurrence of secondary cancer.
Secondary cancer in this review study was found in nine
patients out of 100 who underwent surgery for spinal
ependymoma, suggesting that 9% of patients might de-
velop a de novo tumor.
There are reports supporting the view that gene muta-
tions at different loci on chromosome 22 are associated
with the pathogenesis of spinal ependymomas [15-17].
Several cytogenetic alterations, including deletions and
translocations, constitute the most frequent changes in
this chromosomal region [15,18-20]. In addition, the con-
tribution of other gene mutations on 17p13 and 10q25–
26 loci have been projected as an alternative mechanism
for the pathogenesis of spinal ependymomas [21]. Thus,
all the above might suggest that in patients with spinal
ependymomas the genome in some way is altered. This
combined with the fact that the survival in these pa-
tients is not affected, may give rise to a continuous ac-
cumulation of different gene abnormalities which are
more predisposed to the development of secondary
cancers. The role of molecular imaging by positron
emission tomography in those patients is very important,
and may help to detect a secondary cancer and thus gives
an opportunity for early diagnosis and a better outcome
[22]. So we believe that this may be the reason why pa-
tients with spinal ependymomas might develop second-
ary neoplasia.
Radiotherapy is known to induce cancer. But this is
not the fact in the present case because within the patients
who developed secondary cancer only one was irradiated
and the radiation field was outside the location of the sec-
ond malignancy.
Conclusions
The genetic abnormalities affecting patients with spinal
ependymomas may indicate a predisposition to the de-
velopment of secondary cancers or a general failure of
the repairing mechanism in their DNA. The unaffected
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the accumulation of different mutations on the genome
and thus the appearance of a second cancer. However,
more studies are needed, particularly in young patients
with high survival rates.
Methods
Search strategy for identification of studies
PubMed searches were performed using a wide array of
terms pertinent to spinal cord ependymomas. The exact
search was done using the term -spin* and ependymoma-
(last updated on 12 July 2014). We included studies pub-
lished over the last 30 years (from January 1984). The
reference lists of eligible articles and pertinent reviews were
scrutinized. Two independent investigators for eligibility
evaluated retrieved articles and disagreements were solved
by consensus after discussion with a third investigator.
Data extraction and definitions
This is a review study. From each eligible study we ex-
tracted the following information: author; journal; year;
design; age of the study population; racial descent; whether
analyses had been adjusted for multiple comparisons;
whether analyses were acknowledged to be post hoc; and
details on the definitions of all reported analyses.
From the 1197 related articles retrieved from the
PubMed search, we excluded case reports analyzing less
than four cases; any study involving children; non-English
speaking publications and reports not related to humans;
intracranial ependymomas; and any study with less than
four cases with spinal ependymomas. Information was
captured on all analyses performed and reported in any
format and in any level of detail in the text, figures, tables,
or supplementary material.
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